Archive for April 2018

IMMUNOPRECISE OPENS NEW FULL SERVICE B-CELL FACILITY

Victoria, British Columbia, Canada, April 27, 2018 - IMMUNOPRECISE ANTIBODIES LTD. (“ImmunoPrecise” or “IPA”) (TSX VENTURE: IPA)(OTC PINK: IPATF) announces the opening of its new, innovative full service B-cell facility offering B-cell screening, sorting and sequencing on a broad range of therapeutically-relevant protein families including GPCRs and other multi-membrane spanning proteins.  The immediate benefits to ImmunoPrecise is that … Continue reading

Immunoprecise Announces Oversubscription To Debenture Financing

Victoria, British Columbia, Canada, April 6, 2018 – IMMUNOPRECISE ANTIBODIES LTD. (“ImmunoPrecise”) (TSX VENTURE: IPA)(OTC PINK: IPATF) announces it has completed a final tranche to its debenture (the “Debentures”) financing in the principal amount of $250,000.  In total, ImmunoPrecise issued $4,252,000 of Debentures under the entire financing. The Debentures are unsecured, bear interest at a … Continue reading

IMMUNOPRECISE ACQUIRES MODIQUEST RESEARCH BV

Immediately Accretive by Adding EBITDA of Approximately C$750,000 with Increased Synergies, Scale and Efficiency Strategic Acquisition Allows ImmunoPrecise to Provide Comprehensive and Next Generation Antibody Therapeutic Discovery Victoria, British Columbia, Canada, April 6, 2018 – IMMUNOPRECISE ANTIBODIES LTD. (“ImmunoPrecise” or the “Company”) (TSX VENTURE: IPA)(OTC PINK: IPATF) is pleased to announce that it has acquired … Continue reading